CRACM1 (also called Orai1) constitutes the pore subunit of store-operated calcium release-activated calcium channels. A point mutation in the gene encoding CRACM1 is associated with severe combined immunodeficiency disease in humans. Here we generated CRACM1-deficient mice in which b-galactosidase activity 'reported' CRACM1 expression. CRACM1-deficient mice were smaller in size. Mast cells derived from CRACM1-deficient mice showed grossly defective degranulation and cytokine secretion, and the allergic reactions elicited in vivo were inhibited in CRACM1-deficient mice. We detected robust CRACM1 expression in skeletal muscles and some regions of the brain, heart and kidney but not in the lymphoid regions of thymus and spleen. In contrast, we found CRACM2 expression to be much higher in mouse T cells. In agreement with those findings, the store-operated calcium influx and development and proliferation of CRACM1-deficient T cells was unaffected. Thus, CRACM1 is crucial in mouse mast cell effector function, but mouse T cell calcium release-activated calcium channels are functional in the absence of CRACM1.
In addition to its function in immune cells, a general function for SOC entry has been proposed in pancreatic acinar cells, hepatocytes, and certain types of excitable cells, including neurons, smooth muscle cells, endocrine and neuroendocrine cells 2 . Most of those studies, however, did not specifically demonstrate a function for CRAC channels. Here we detected expression of a fusion protein of b-galactosidase and CRACM1 in several excitable cell types, including skeletal muscle cells. Along with the observation that two patients with SCID who have mutations in the gene encoding CRACM1 also suffer from unexplained congenital nonprogressive myopathy 4 , our data indicate that CRACM1 might be involved in SOC entry in some types of excitable cells.
RESULTS

The generation of CRACM1-deficient mice
We generated Cracm1 -/-mice with gene-trap technology 16 . We obtained embryonic stem cell line XL922 with a disrupted Cracm1 gene from gene-trapping source 17 . In the embryonic stem cells, the gene-trap vector pGT0Lxf, which is 8.5 kilobases in length and is composed of a splice-acceptor site followed by a 'bGeo' cassette encoding a fusion of b-galactosidase and neomycin phosphotransferase, was inserted in the first intron of Cracm1 ( Supplementary Fig. 1a online). We injected XL922 embryonic stem cells into mouse blastocysts to generate chimeric mice. We bred transmitting chimeras to generate Cracm1 +/-mice, which we intercrossed to produce Cracm1 -/-mice. We used Southern blot analysis to confirm the presence of the gene-trap vector in embryonic stem cells and for genotyping mice ( Supplementary Fig. 1b ). As expected, hybridization of HindIII-digested genomic DNA from tail tissue with a Cracm1-specific probe demonstrated an 11-kilobase band for the wild-type allele and a 19.5-kilobase band for the trapped allele ( Supplementary  Fig. 1b ). To rule out the possibility of any additional insertions of the gene-trap vector in the genome, we stripped that same blot and rehybridized it with probes specific for b-galactosidase and neomycin phosphotransferase. Each probe yielded a single band of 19.5 kilobases (data not shown).
Initially, we failed to obtain any Cracm1 -/-pups. However, special housing conditions ensured the survival of Cracm1 -/-mice, which were much smaller until they reached maturity (Fig. 1a) . We obtained the expected mendelian ratios of Cracm1 +/+ , Cracm1 +/-and Cracm1 -/-pups after splitting and fostering litters born to Cracm1 +/-intercrosses, housing no more than three to four pups per dam. Wholebody necropsy and extensive histological analysis of Cracm1 -/-pups showed no obvious abnormalities (data not shown).
To identify physiological functions for CRAC channels and to determine the reason for the overall smaller size of Cracm1 -/-mice, we stained tissues with X-gal (5-bromo-4 chloro-3-indolyl-b-Dgalactosidase) to detect b-galactosidase activity, which 'reports' Cracm1 expression, in newborn Cracm1 +/+ and Cracm1 -/-pups (Fig. 1b) . Unexpectedly, we noted robust X-gal staining in almost all skeletal muscles ( expression in different regions of the brain; and some parts of the heart also showed faint expression. As CRAC channels are indispensable mainly in unexcitable cells, these observations raise the possibility that CRAC channels may also influence the function of excitable cells.
CRACM1 in mast cell effector functions
Because the CRAC channel current (I CRAC ) has been characterized extensively in mast cell lines, we sought to analyze the precise function of CRAC channel-mediated Ca 2+ influx in effector functions of primary mast cells. We derived mast cells from fetal livers at embryonic day 15.5, as Cracm1 -/-mice were smaller and initially failed to survive. We cultured fetal liver suspensions for 5 weeks with IL-3 and stem cell factor. After 5 weeks and before each assay, we counted cells derived from Cracm1 +/+ , Cracm1 +/-and Cracm1 -/-fetal livers and stained them with antibodies specific for FceRI a-chain and the stem cell factor receptor c-Kit ( Supplementary Fig. 2a ,b online). Mast cell numbers and expression of FceRI and c-Kit were similar in all three groups, which suggested that mast cell proliferation and maturation in vitro were not affected by the absence of CRACM1. In addition, as binding of monomeric IgE to FceRI in the absence of antigen increases FceRI expression 18 , we incubated Cracm1 +/+ , Cracm1 +/-and Cracm1 -/-fetal liver-derived mast cells overnight with IgE and measured the upregulation of FceRI. All three groups showed similar FceRI upregulation ( Supplementary Fig. 2c ).
To study the effect of CRACM1 deletion on mast cell degranulation, we loaded mast cells overnight with [ 3 H]serotonin and dinitrophenyl (DNP)-specific IgE. The next day, we washed the cells and incubated them for 20 min with 'titrating' doses of the antigen DNP-human serum albumin (DNP-HSA). Serotonin release triggered by antigenmediated FceRI crosslinking was abolished in Cracm1 -/-and was much lower in Cracm1 +/-mast cells (Fig. 2a) . Notably, Cracm1 -/-but not Cracm1 +/-cells showed complete inhibition of degranulation in response to saturating doses of phorbol 12-myristate 13-acetate (PMA, a protein kinase C agonist) and ionomycin (which depletes Ca 2+ stores and induces CRAC channel opening; Fig. 2b ) 19 .
Serotonin is stored in preformed granules and is released after mast cell activation, whereas arachidonic acid metabolites are synthesized anew. We next investigated whether CRACM1 deletion affected the synthesis of the arachidonic acid metabolite leukotriene C4 (LTC 4 ). We incubated mast cells overnight with DNP-specific IgE, stimulated them for 30 min with various doses of DNP-HSA and measured LTC 4 in the supernatants by enzyme immunoassay. FceRI aggregationinduced production of LTC 4 was abolished in Cracm1 -/-mast cells and was much lower in Cracm1 +/-mast cells (Fig. 2c) . Next we investigated the effect of CRACM1 deficiency on cytokine secretion by mast cells. Tumor necrosis factor (TNF) is stored in granules as well as being synthesized anew after FceRI triggering, whereas IL-6 is synthesized only after FceRI triggering. Mast cell TNF production is dependent on the NFATc1 and NFATc2 transcription factors 20 , whereas IL-6 production requires the transcription factor NF-kB 21 .
Cracm1 -/-mast cells produced much less TNF than did Cracm1 +/+ mast cells in response to various doses of antigen or stimulation with PMA and ionomycin ( Fig. 2d,e) . Cracm1 +/-mast cells had a less severe defect in TNF production. In contrast, IL-6 secretion induced by antigen but not that induced by PMA and ionomycin was impaired in Cracm1 -/-mast cells, and Cracm1 +/-produced normal amounts of IL-6 in response to all stimuli ( Fig. 2f,g ). Real-time PCR of mRNA isolated from Cracm1 +/+ , Cracm1 +/-and Cracm1 -/-mast cells showed similar expression of CRACM2 and CRACM3 homologs (Fig. 2h) . Therefore, CRACM2 and CRACM3 may account for the partial activation of IL-6 secretion in CRACM1-deficient mast cells. These results collectively suggest that CRACM1 is indispensable for mast cell degranulation and the secretion of lipid mediators and for the secretion of some but not all cytokines.
To assess the function of CRACM1 in allergic reactions involving tissue-resident mast cells, we used an in vivo IgE-mediated model of passive cutaneous anaphylaxis (PCA) 22 . We injected DNP-specific IgE into the left ears of Cracm1 -/-and Cracm1 +/+ littermates and injected right ears with saline. Then, 1 d later, we induced an immediate-type allergic reaction by intravenous injection of the antigen DNP-HSA and Evan's blue dye. In PCA, FceRI-induced mast cell activation results in the release of several vasoactive substances, which increase vascular permeability. This effect can be quantified by measurement of the local accumulation of Evan's blue dye leaving the vessels in the IgEsensitized area. At 1 h after injecting antigen, we killed mice and extracted dye from the ears as described 23 . In accordance with our in vitro mast cell studies, IgE-dependent PCA reactions were abolished in Cracm1 -/-mice (Fig. 3a) . To confirm that the inhibition of PCA was indeed due to a defect in mast cell effector function and not to an indirect effect of fewer mast cells in Cracm1 -/-tissues, we quantified mast cells in Cracm1 -/-and Cracm1 +/+ ears. We noted similar numbers of mast cells in Cracm1 -/-and Cracm1 +/+ ears (Fig. 3b,c) .
SOC entry and I CRAC in mast cells
Next we sought to correlate functional defects with the extent of receptor-stimulated and store-operated Ca 2+ influx in Cracm1 -/-mast cells. First we measured the effect of CRACM1 deletion on Ca 2+ release and influx induced by antigen-mediated FceRI crosslinking. Release of endoplasmic reticulum Ca 2+ was similar in Cracm1 +/+ , Cracm1 +/-and Cracm1 -/-mast cells (Fig. 4a) . Treatment with ionomycin in Ca 2+ -free medium confirmed that Cracm1 -/-cells had normal concentrations of Ca 2+ stored in the endoplasmic reticulum ( Supplementary Fig. 3 online) . Ca 2+ influx was inhibited by 70% in Cracm1 -/-cells but by only 10-20% in Cracm1 +/-cells. To verify that the residual Ca 2+ influx was indeed store operated, we used thapsigargin, an inhibitor of the sarcoendoplasmic reticulum Ca 2+ -ATPase that is responsible for pumping Ca 2+ into endoplasmic reticulum stores, to deplete the endoplasmic reticulum Ca 2+ stores. We loaded cells with the fluorescent Ca 2+ indicator Fura-5F and bathed them in HEPES-buffered salt solution containing 1 mM extracellular Ca 2+ . We measured changes in the intracellular Ca 2+ concentration at the singlecell level. Thapsigargin treatment induced SOC entry in Cracm1 +/+ , Cracm1 +/-and Cracm1 -/-mast cells (Fig. 4b) . However, whereas Cracm1 +/+ and Cracm1 +/-mast cells had similar peak Ca 2+ entry (Fig. 4c) and rates of Ca 2+ entry (Fig. 4d) , these properties were deficient but not absent in Cracm1 -/-mast cells. In both Cracm1 +/+ and Cracm1 -/-mast cells, the observed thapsigargin-induced Ca 2+ entry was completely blocked by inhibitors of CRAC currents, either 1 mM Gd 3+ (Fig. 4e) . 4f ), which indicated that the residual Ca 2+ entry was mediated by CRAC channels.
We also measured I CRAC in mast cells. We measured whole-cell SOC currents with a pipet solution containing inositol triphosphate and BAPTA (1,2-bis(o-aminophenoxy)ethane-N,N ,N¢,N¢-tetraacetic acid), a Ca 2+ -specific chelator, to actively deplete intracellular Ca 2+ stores. We noted inwardly rectifying currents with densities of -0.85 ± 0.13 pA/pF in Cracm1 +/+ mast cells bathed in HEPESbuffered salt solution containing 20 mM Ca 2+ (Fig. 5a,b) . This current was completely abolished by 3 mM Gd 3+ . However, Cracm1 -/-mast cells completely lacked detectable Ca 2+ CRAC currents. Because our Ca 2+ -imaging experiments (Fig. 4) showed small residual SOC entry in Cracm1 -/-mast cells, we considered the possibility that a small component of I CRAC might have remained that was not readily detectable because of the very small size of the Ca 2+ I CRAC. We therefore used a protocol with a divalent cation-free extracellular solution, which amplifies a very small I CRAC into a more readily detectable range 24 . In Cracm1 +/+ mast cells, a peak Na + I CRAC developed in the range of -14.57 ± 1.41 pA/pF (Fig. 5c,d) . Notably, we also detected Na + CRAC currents in Cracm1 -/-mast cells, with current densities of -4.95 ± 0.43 pA/pF. These Na + currents were also inwardly rectifying, characteristic of CRAC channels.
To verify that the currents in the Cracm1 -/-mast cells were indeed store operated, we did passive store-depletion experiments with only BAPTA (to chelate cytosolic Ca 2+ ) in the pipet. We focally applied divalent cation-free solutions intermittently to detect current development in the Cracm1 -/-cells. In Cracm1 +/+ mast cells, I CRAC developed after a delay because of the slow depletion of internal Ca 2+ stores in these conditions (Fig. 5e) . Notably, in Cracm1 -/-mast cells, the inwardly rectifying currents noted in active store-depletion experiments were also detected in the passive store-depletion experiments (Fig. 5f) . The peak Ca 2+ and Na + current densities were very similar to those noted in the active depletion experiments. These data suggest that the small Ca 2+ influx and I CRAC detected in Cracm1 -/-cells were presumably due to other at least partially compensatory CRACM isoforms. Finally we sought to determine if the functional defect in Cracm1 -/-mast cells could be reconstituted by forced expression of CRACM1. For this, we transduced Cracm1 -/-mast cells with a bicistronic retrovirus encoding CRACM1 plus green fluorescent protein (GFP) or GFP alone. The transduction efficiency of Cracm1 -/-mast cells was 25-30%, as assessed by GFP expression ( Supplementary Fig. 4 online). Cracm1 -/-mast cells reconstituted with CRACM1 showed a reversal in the inhibition of serotonin release when stimulated with PMA and ionomycin, and recovery of degranulation was commensurate with the efficiency of reconstitution (Fig. 6) .
T lymphocyte development and effector function As CRACM1 is important for human T lymphocyte proliferation and effector functions 15 , the lack of b-galactosidase staining 'reporting' Cracm1 expression in the lymphoid areas of thymus and spleen in our reporter mice was unexpected (Fig. 7a) . Because CRACM1-mutant patients with SCID have a rudimentary thymus 15 , we examined the thymi of 5-week-old Cracm1 +/+ and Cracm1 -/-mice. We noted no differences in the percentages of CD4 + CD8 + double-positive and CD4 + and CD8 + single-positive thymocytes (Fig. 7b) or in the proportions of T cell and B cell populations in the spleen (data not shown).
The proliferation of Cracm1 -/-splenic T cells in response to stimulation with antibody to CD3 (anti-CD3) and anti-CD28 was not significantly different from that of Cracm1 +/+ and Cracm1 +/-T cells (Fig. 8a) . However, Cracm1 -/-T cells secreted less IL-2 and IFN-g than their Cracm1 +/+ counterparts (Fig. 8b,c) . In contrast, SOC influx was similar in Cracm1 +/+ and Cracm1 -/-T cells (Fig. 8d-g and data not shown). The lack of effect of CRACM1 deletion on mouse T cell development and proliferation was consistent with the absence of CRACM1-b-galactosidase expression in the mouse thymic and spleen lymphoid areas. However, it was possible that b-galactosidase staining did not correlate with Cracm1 expression in tissues. To rule out that possibility, we measured CRACM isoform expression in thymocytes and spleen and lymph node T cells from Cracm1 +/+ , Cracm1 +/-and Cracm1 -/-littermates by real-time PCR. Cracm1 expression was indeed negligible, as was Cracm3 expression ( Supplementary Fig. 5 online). However, we noted much higher expression of Cracm2 in thymocytes and T cells. These data suggest that CRACM2 may be the dominant CRACM isoform used in mouse T cell CRAC channels.
DISCUSSION
Mast cells have long been known as critical effectors of allergic disorders. However, they are now being recognized for having many crucial functions at the interface of innate and adaptive immune responses. To accomplish such diverse effector functions, mast cells use a varied range of effector mechanisms, including degranulation of preformed secretary granules and secretion of chemokines, inflammatory cytokines and leukotrienes. We have shown here that a poreforming subunit of CRAC channels, CRACM1, was crucial for mast cell degranulation and LTC 4 secretion as well as TNF secretion. Furthermore, we have shown that induction of the IgE-mediated passive anaphylaxis response in vivo was also dependent on CRACM1. In contrast, mast cell secretion of IL-6 was only partially affected by the absence of CRACM1.
Many studies have established Ca 2+ as being crucial in mast cell effector function 25 . The resting cytosolic Ca 2+ concentrations in most unexcitable cells are close to 100 nM. Release of endoplasmic reticulum Ca 2+ elicits a transient two-to threefold increase in cytosolic Ca 2+ concentrations, whereas store-dependent Ca 2+ influx raises the cytosolic Ca 2+ concentration almost tenfold. Therefore, it is likely that different amplitudes or different sites of cytosolic Ca 2+ increase activate distinct signaling pathways in mast cells, thereby allowing the execution of various effector functions. Involvement of a sustained Ca 2+ increase in mast cell secretion has been demonstrated 26, 27 . The identification of CRACM1 as the pore-forming subunit of CRAC channels allowed us to directly test the influence of CRAC channelmediated Ca 2+ influx on mast cell effector function.
CRACM1 deletion completely abolished mast cell degranulation in response to antigen-mediated crosslinking of FceRI and saturating doses of PMA and ionomycin. The loss of response to PMA and ionomycin was unexpected, as the concentration of ionomycin used here (2 mM) was sufficient to cause a large nonspecific increase in cytoplasmic Ca 2+ in addition to activating the I CRAC . However, a growing body of literature has indicated that many cellular responses are more efficiently activated by Ca 2+ entering through the CRAC channels than by nonspecific increases in Ca 2+ , even when the nonspecific increases are much larger on a global scale 13, 14, [28] [29] [30] . Thus, our findings obtained with Cracm1 -/-mast cells allow us to make the point that although immunologists often use ionomycin and PMA to 'bypass' initial signaling steps, in fact Ca 2+ influx through CRAC channels may actually constitute the functionally relevant component of PMA and ionomycin-induced cytosolic Ca 2+ alterations. Consistent with that interpretation, the endoplasmic reticulum-mediated transient increase in cytosolic Ca 2+ was unaffected by CRACM1 deletion, but degranulation was blocked. What is the precise function of CRAC channel-mediated Ca 2+ influx in degranulation? Perhaps Ca 2+ promotes granule exocytosis by binding C2 domains of synaptotagmins, a family of Ca 2+ sensors that have emerged as key participants in membrane fusion in cells capable of regulated secretion, such as mast cells and neurons 31, 32 .
The secretion of newly synthesized lymphokines and lipid mediators by mast cells is independent of degranulation (with the exception of TNF, some of which is stored in granules). Therefore, inhibition of the secretion of LTC 4, TNF and IL-6 may involve pathways distinct from those regulating degranulation. In mast cells, TNF secretion requires activation and nuclear translocation of NFAT 20 . CRAC channel-dependent Ca 2+ flux is crucial for the nuclear translocation of NFAT proteins in T lymphocytes 33, 34 . Because Cracm1 -/-mast cells stimulated with PMA and ionomycin also showed negligible TNF secretion, it is reasonable to propose that CRACM1 deletion affects TNF secretion by inhibiting I CRAC -induced NFAT activation.
Cracm1 -/-mast cells showed only partial inhibition of IL-6 secretion. Unlike TNF secretion, IL-6 secretion requires NF-kB activation 21 . In T cells, the strength of T cell receptor signals determines the frequency of oscillations in cytosolic Ca 2+ . Whereas NFAT nuclear translocation requires oscillations with periods of less than about 6 min, the requirements for NF-kB activation are considerably less stringent, as NF-kB activity is noted even at much longer interspike intervals of 30 min (ref. 35) . Thus, the activation of NFAT versus NF-kB is determined by the frequency of Ca 2+ oscillations, which in turn can be 'translated' into the activation of specific cytokine gene enhancers. Similarly, distinct signaling pathways that result in the secretion of different chemokines and cytokines are elicited depending on the degree of FceRI occupancy 36 . The small SOC influx seen in Cracm1 -/-cells, therefore, might be sufficient to partially activate NF-kB, resulting in submaximal IL-6 secretion.
Notably, wild-type mast cells expressed similar amounts of CRACM1, CRACM2 and CRACM3. Thus, CRACM2 and CRACM3 may account for the residual SOC entry, I CRAC and IL-6 secretion noted in Cracm1 -/-mast cells. However, CRACM2 and CRACM3 could not compensate for the defects in mast cell effector function. Likewise, in patients with SCID, CRACM2 and CRACM3 do not compensate for mutant CRACM1 in T cell function 37 . Therefore, even though all three CRACM proteins have been shown to carry storeoperated CRAC currents in vitro, they may be regulated differently and thus function in a nonredundant way in vivo. Indeed, the three CRACM proteins differ in their inhibition by cytosolic Ca 2+ (refs. 24, 38) . Moreover, the average current amplitudes of CRACM2 and CRACM3 were found to be much smaller than the corresponding amplitude of CRACM1 in overexpression studies in HEK293 cells 24, 38 . Nevertheless, the weak but detectable SOC entry and I CRAC in Cracm1 -/-mast cells expressing normal amounts of CRACM2 and CRACM3 suggest that in physiological conditions, CRACM2 and/or CRACM3 are/is capable of forming functional CRAC channels. The weak SOC entry and I CRAC amplitudes suggest that smaller singlechannel conductance or open probability for CRACM2 and/or CRACM3 channels may be sufficient to drive the activation of some but not all transcription factors. Studies of mice lacking CRACM2 and/or CRACM3 should address these possibilities.
CRACM1 deficiency did not substantially affect the development and proliferation of T cells. Although these findings seem to contradict the reported function of CRACM1 in human T cells 4, 15 , our results suggest that CRACM2, rather than CRACM1, might be the dominant CRAC channel protein used by mouse T cells. We did not detect CRACM1 expression in the thymic and splenic lymphoid areas of newborn 'reporter mice' , and wild-type mouse thymocytes and T cells had much higher expression of CRACM2 mRNA than CRACM1 and CRACM3 mRNA. In addition, we noted normal SOC entry in Cracm1 -/-T cells. IL-2 and IFN-g secretion were inhibited but not abolished in Cracm1 -/-T cells, perhaps as a result of the lower expression of CRACM2 in Cracm1 -/-T cells. Thus, the differences between human and mouse in Cracm1 -/-T cell phenotypes are probably due to species-specific use of CRACM homologs.
In addition to having a defect in T cell effector functions, human patients with SCID develop a nonprogressive myopathy 4, 15 . As we detected robust expression of CRACM1 in skeletal muscle cells and in several regions of the brain, such observations suggest a potential function for CRAC channels in excitable cells. Moreover, there are many similarities between the processes of synaptic vesicle fusion in neurons and exocytosis of secretary granules in mast cells 25, 39 . A function for CRAC channels in skeletal muscles might also explain the smaller size of Cracm1 -/-mice. Given these observations, it will be useful to investigate the physiological functions of CRAC channels in other tissues, such as skeletal muscle, brain, heart and kidney.
METHODS
Derivation of mast cells from embryonic livers. Pregnant Cracm1 +/-female mice from Cracm1 +/-intercrosses were killed by CO 2 inhalation at day 15 after conception. Embryos were removed and were washed with PBS. Livers extracted from each embryo were 'teased apart' to produce single-cell suspensions. Cells were differentiated for 5 weeks in complete Iscove's medium containing IL-3 and stem cell factor (20 ng/ml each). At the end of 5 weeks and before each assay, cells were stained with anti-FceRI a-chain (MAR-1; eBiosciences) for quantification of the proportion of mast cells in the population.
Degranulation assays. Mast cells at a density of 3 Â 10 6 cells per well in sixwell tissue culture plates were loaded for 16 h (at 37 1C and 5% CO 2 ) with [ 3 H]5-hydroxycreatinine ([ 3 H]serotonin; 1 mCi per 1 Â 10 6 cells) and with DNP-specific IgE (0.5 mg/ml). The next day, cells were washed, were plated in 96-well round-bottomed plates at a density of 1 Â 10 5 cells per well and were incubated for 10 min at 37 1C. DNP-HSA (final concentration, 0-50 ng/ml) was added to crosslink FceRI. After 20 min at 37 1C, degranulation was stopped by placement of the plates on ice for 5 min. Aliquots (100 ml) were taken from triplicate wells and were pooled for scintillation counting. Total cellular incorporation of [ 3 H]serotonin was determined from 1% (vol/vol) Nonidet-P40 lysates. LTC 4 assays. LTC 4 was measured in 1 Â 10 6 IgE anti-DNP-loaded mast cells triggered with DNP-HSA (0-50 ng/ml). Supernatants were collected 30 min after triggering and LTC 4 was measured with an enzyme-linked immunosorbent assay kit according to the manufacturer's instructions (Cayman Chemical).
TNF and IL-6 assays. Mast cells (1 Â 10 6 ) loaded with IgE anti-DNP were triggered for 6 h with DNP-HSA (0-50 ng/ml). TNF and IL-6 in the supernatant were measured by enzyme-linked immunosorbent assay. Coating and detection antibodies specific for TNF and IL-6 were from BD Biosciences.
Passive cutaneous anaphylaxis. Mice were anesthetized with Avertin and were injected intradermally with 25 ng IgE anti-DNP (left ears) or saline (right ears). Injection sites were marked on the skin. Then, 1 d after IgE injection, anesthetized mice received 100 ml DNP-HSA (1 mg/ml) containing 2% (wt/vol) Evan's blue dye, injected intravenously. Then, 1 h later, mice were killed and their ears were excised. Dye was extracted with formamide and absorbance was measured at 610 nm.
Tissue mast cell staining. Whole left and right ears of Cracm1 -/-and Cracm1 +/+ mice were excised and were fixed overnight in 10% (wt/vol) neutral buffered formalin. The next day, fixed ears were embedded in paraffin and cut into sections. For identification of mast cells, sections were stained for 5 min with 0.1% (wt/vol) toluidine blue, then were washed and analyzed. Cells were counted with a Nikon Eclipse E400 microscope at Â40 magnification.
Single-cell Ca 2+ measurement. The intracellular Ca 2+ concentration in primary mast cells loaded with Fura-5F was measured as described 40 . Mast cell were plated on round coverslips 30 mm in diameter, which were mounted in a Teflon chamber and incubated for 25 min at 37 1C in the dark in DMEM with 1 mM acetoxymethyl ester of Fura-5F (Fura-5F AM; Molecular Probes). For measurement of intracellular Ca 2+ concentrations, cells were bathed at 25 1C in HEPES-buffered salt solution (120 mM NaCl, 5.4 mM KCl, 0.8 mM Mg 2 SO 4 , 20 mM HEPES, 1.0 mM CaCl 2 and 10 mM glucose, pH 7.4). Nominally Ca 2+ -free solutions were HEPES-buffered salt solution with no added CaCl 2 . Fluorescence images of the cells were recorded and analyzed with a digital fluorescence imaging system (InCyt Im2; Intracellular Imaging) 40 . Changes in intracellular Ca 2+ concentration are expressed as the Fura-5F fluorescence ratio (F340/F380) after correction for the contributions of autofluorescence. Mast cells were exposed to test solutions by exchanging of the bathing solution.
Electrophysiology. Currents were analyzed at 25 1C with the patch-clamp technique in the whole-cell configuration as described 24 . The extracellular solution contained 145 mM NaCl, 3 mM KCl, 10 mM CsCl, 1.2 mM MgCl 2 , 10-20 mM CaCl 2 , 10 mM glucose and 10 mM HEPES, pH 7.4. The standard divalent cation-free solution contained 155 mM Na-methanesulfonate, 10 mM HEDTA, 1 mM EDTA and 10 mM HEPES, pH 7.4. Fire-polished pipets were filled with 145 mM Cs-methanesulfonate, 20 mM BAPTA, 10 mM HEPES and 8 mM MgCl 2 , pH 7.2.
X-gal staining. Newborn pups were killed and then fixed in 4% (wt/vol) paraformaldehyde. After fixation, they were washed and frozen in optimum cutting temperature medium on dry ice. Frozen tissue was cut into cryosections 20 mm in thickness, and sections were fixed with 0.25% (wt/vol) glutaraldehyde, were washed, and were stained overnight at 37 1C with X-gal-containing staining solution. Stained sections were visualized with a light microscope.
T cell proliferation and cytokine assays. Spleen cell suspensions were plated at a density of 2 Â 10 5 cells per well and were stimulated for 48 h with 'titrated' doses (0.01-0.3 mg/ml) of soluble anti-CD3 and anti-CD28 in 96-well flatbottomed plates. Proliferation was measured by incorporation of [ 3 H]thymidine for the final 6 h. For estimation of cytokine concentrations, 100-ml supernatants were collected from replicate 96-well plates. Triplicate samples were pooled and diluted 1:2 in PBS. Cytokine concentrations were determined with the Bio-Plex Mouse Cytokine 23-Plex Panel (BioRad) according to the manufacturer's specifications.
Additional methods. Information on mice, Southern blot analysis, retroviruses, isolation of RNA and quantitative PCR, antibodies and flow cytometry is available in the Supplementary Methods online.
Note: Supplementary information is available on the Nature Immunology website.
